Investor Relations

Notice is hereby given of the Annual General Meeting of Ambu A/S, CVR no. 63 64 49 19, which is held on 

Wednesday, 2 December 2026 at 3:00 pm (CET)

at the Company’s address at Baltorpbakken 13, 2750 Ballerup.

BOARD OF DIRECTORS
The Board of Directors proposes re-election of Jørgen Jensen as Chair of the Board and Shacey Petrovic as Vice Chair. The Board of Directors proposes that David Hale, Simon Hesse Hoffmann, Susanne Larsson, and Michael del Prado all are re-elected as members of the Board of Directors. Additionally, the Board of Directors proposes that Jose Ignacio (Nacho) Abia Buenache be elected as a new member of the Board of Directors.

The notice for this year’s Annual General Meeting, including information about the proposed Board candidates, is enclosed. This notice is available in Danish- and English-language versions. In the event of discrepancies, the English version shall prevail.

Ambu A/S offers the possibility of viewing the Annual General Meeting 2026 via live webcast on Ambu’s website.

Please refer to the notice for further information.
 

Download the notice in English here.

Download the notice in Danish here.

Ambu A/S is initiating a new share buyback program, under which Ambu will repurchase shares for a total amount of up to DKK 400m. The program will be conducted in the period from 9 November 2026 until no later than 30 April 2027.

The share buyback program is being launched within the authority granted by the shareholders at the Annual General Meeting held on 14 December 2022, for the repurchase of up to 10% of the Company’s share capital, provided that the purchase price does not deviate by more than 10% from the most recently quoted market price for the Company’s B-shares at the time of the acquisition. Prior to the launch of the share buyback program, Ambu holds 8,641,687 treasury shares, equal to 3.2% of the Company’s share capital.

The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations, with the purpose of reducing the share capital as set out in Article 5(2)(a) in MAR.

Ambu has retained Danske Bank to act as lead manager of the share buyback program and purchase shares on behalf of Ambu. Danske Bank has also agreed under the contract to make its trading decisions in relation to the shares in the Company independently of, and without influence by, the Company.

Ambu reserves the right to suspend or terminate the share buyback program at any time. Should the share buyback program be suspended or terminated, Ambu will announce this in a company announcement, and the manager will stop buying back shares in the market.

Terms of the share buyback program
Under the share buyback program, Ambu may repurchase shares up to a maximum amount of DKK 400m, and no more than 10,000,000 shares, corresponding to approximately 3.7% of the share capital of the Company.

The shares will be purchased on Nasdaq Copenhagen (XCSE) and potentially other Multilateral platforms.

The shares bought back on each trading day may not exceed 15% of the average daily trading volume over the 20 trading days preceding the date of purchase.

Shares acquired under the share buyback program may not be bought at a price exceeding the higher of (i) the share price of the last independent transaction, and (ii) the highest independent bid on the shares on the trading venue where the transaction is executed. Further, shares may not be bought at a price deviating by more than 10% from the official price quoted on Nasdaq Copenhagen at the time of acquisition for the Company’s B-shares.

In accordance with the Safe Harbor Regulations, Ambu will as a minimum for every seventh trading day issue an announcement in respect of transactions made under the share buyback program.

Download the company announcement here.

Today, Ambu releases its Annual Report for the 2025/26 financial year. For the full year, Ambu delivered 10.1% organic revenue growth, driven by 16.4% growth in Endoscopy Solutions. Respiratory grew organically by 14.6%, while Urology, ENT & GI continued solid momentum with 18.2%. Anesthesia & Patient Monitoring grew 0.4%, positively driven by our market-leading portfolio in a stable and growing market, however, offset by lower volumes in Anesthesia following price increases. Ambu’s EBIT margin reached 13.2%, reflecting an improvement in operating scale, offset by strategic investments to drive future growth.

For 2026/27, Ambu expects to deliver organic revenue growth of 9.5-11.5% and an EBIT margin of 13-15%. Endoscopy Solutions will remain the key growth driver, with organic growth expected at around 15%.

 

“I’m proud of another strong year for Ambu and the healthcare partners we serve. 2025/26 marked an important first year of our ZOOM AHEAD strategy as we pursue our ambition to achieve global endoscopy leadership. We delivered our third consecutive year of double-digit organic revenue growth, reaching 10.1%, within the guidance range we set at the beginning of the year. Endoscopy Solutions grew more than 15% for the fourth year in a row, fueled by broad-based momentum across all areas. This further strengthens our position as the market leader driving the transition from reusable to single-use endoscopy.

We enter the new financial year from a position of strength, with clear ambitions to keep that momentum going. Innovation has been at the heart of Ambu for almost 90 years, and over the next 12 to 24 months, we are preparing for new product approvals across all our endoscopy areas, taking our full-solution offering to the next level.

A big thank you to all our Ambu team members for their dedication and drive, and to our customers and partners for their continued trust. I’m excited about what lies ahead and the impact we can make for healthcare partners and patients worldwide.”

Britt Meelby Jensen
Chief Executive Officer

 

Financial highlights for 2025/26

• Revenue for the full year was DKK 6,471m (DKK 6,037m), bringing the organic growth to 10.1% (13.1%).
• Endoscopy Solutions increased organically by 16.4% (15.4%). Respiratory posted 14.6% (11.4%) organic growth, while Urology, ENT & GI posted 18.2% (19.6%) organic growth.
• Anesthesia & Patient Monitoring increased organically by 0.4% (9.9%).
• Geographic regions, Europe and Rest of World delivered solid growth of 9.1% (13.3%) and 9.6% (9.2%), respectively, while North America delivered strong growth of 11.0%  (13.8%), driven by Endoscopy Solutions.
• EBIT was DKK 851m (DKK 784m), with an EBIT margin of 13.2% (13.0%).
• Free cash flow (FCF) before acquisitions totaled DKK 487m (DKK 407m) for the full year.
• Total cash distribution worth of DKK 559m was paid out in 2025/26, consisting of DKK 109m in dividends and DKK 450m in share buybacks.
• Capital return to shareholders of DKK 551m is planned for 2026/27, comprising a proposed dividend of DKK 151m, subject to approval at the Annual General Meeting, and a DKK 400m share buyback program.

2026/27 financial guidance

• Organic revenue growth: 9.5-11.5%
• EBIT margin: 13-15%

DOWNLOAD ALL 2025/26 STATUTORY REPORTS

In addition to the Annual Report, which includes the Company’s sustainability statement, Ambu also publishes its interim report for Q4 2024/25, Remuneration Report, and Corporate Governance Report for the 2025/26 financial year today.

All statutory reports can be accessed on Ambu.com/reports:

• Annual Report 2025/26
• Annual Report 2025/26 (ESEF-tagged version)
• Remuneration Report 2025/26
• Corporate Governance Report 2025/26